R. Kirk McPherson - Concepedia

Concepedia

Author

R. Kirk McPherson

Pfizer (United States)

Also Known As

Brittanee Despres, McPherson, R.K., R K McPherson, R Kirk McPherson, R. K. McPherson, R. Kirk McPherson, R.K. McPherson, R.Kirk McPherson, Rachel Mcpherson

31

Publications

1.5K

Citations

20

H-Index

47

Concepts

All Affiliations

Pfizer (United States)

RK

About

R. Kirk McPherson is an author at Pfizer (United States) specializing in medicine, pharmacology, and biochemistry.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	20	22	1.5K
2	Biochemistry	17	18	1.2K
3	Natural Sciences	10	10	461
4	Health Sciences	8	8	697
5	Cell Biology	4	4	258

R. Kirk McPherson

×

24

Publications

1.5K

Citations

20

H-Index

	Year	Citations
Discovery of a human liver glycogen phosphorylase inhibitor that lowers blood glucose <i>in vivo</i> William H. Martin, Dennis J. Hoover, Sandra J. Armento, Proceedings of the National Academy of Sciences GlycobiologyMetabolic RemodelingExperimental PharmacologyCp-91149 AdministrationMetabolic Syndrome	1998	230
Human liver glycogen phosphorylase inhibitors bind at a new allosteric site Virginia L. Rath, Mark Ammirati, Dennis E. Danley, Chemistry & Biology BiochemistryMedicineLiver PhysiologyNew Allosteric SiteGlycogen Phosphorylase Inhibitors	2000	126
Transgenic mice expressing the human GLUT4/muscle-fat facilitative glucose transporter protein exhibit efficient glycemic control. M L Liu, E. Michael Gibbs, Scott C. McCoid, Proceedings of the National Academy of Sciences Glucose HomeostasisTransgenic MiceInsulin SignalingObesityMetabolic Syndrome	1993	104
Enhanced peripheral glucose utilization in transgenic mice expressing the human GLUT4 gene. Judith L. Treadway, D. M. Hargrove, Nancy A. Nardone, Journal of Biological Chemistry Transgenic Mouse ModelsFree Fatty AcidsGlucose HomeostasisTransgenic MiceCaloric Restriction	1994	102
Indole-2-carboxamide Inhibitors of Human Liver Glycogen Phosphorylase Dennis J. Hoover, Sheri Lefkowitz-Snow, Jana L. Burgess-Henry, Journal of Medicinal Chemistry Cardiovascular PharmacologyAltmetric Attention ScorePharmacotherapyTranslational PharmacologyMolecular Pharmacology	1998	102
Discovery of PF-04620110, a Potent, Selective, and Orally Bioavailable Inhibitor of DGAT-1 Robert L. Dow, Jiancheng Li, Michael P. Pence, ACS Medicinal Chemistry Letters Pharmaceutical SciencePharmacotherapyPharmaceutical ChemistryInsulin SignalingMetabolic Syndrome	2011	100
Actions of Novel Antidiabetic Agent Englitazone in Hyperglycemic Hyperinsulinemic <i>ob</i>/<i>ob</i> Mice Ralph W. Stevenson, Nancy J. Hutson, Michael N Krupp, Diabetes Metabolic SyndromeDiabetes ManagementBiochemistryMedicineCp 68722	1990	97
Anilinoquinazoline Inhibitors of Fructose 1,6-Bisphosphatase Bind at a Novel Allosteric Site: Synthesis, In Vitro Characterization, and X-ray Crystallography Stephen W. Wright, Anthony Carlo, Maynard D. Carty, Journal of Medicinal Chemistry Drug TargetBioorganic ChemistryNovel Allosteric SiteAnilinoquinazoline InhibitorsAllosteric Inhibitors	2002	81
Effects of skyrin, a receptor-selective glucagon antagonist, in rat and human hepatocytes. Jeremy C. Parker, R. Kirk McPherson, Kim Andrews, Diabetes Cellular PharmacologyPharmacotherapyExperimental PharmacologyInsulin SignalingMolecular Pharmacology	2000	63
Discovery of small molecule isozyme non-specific inhibitors of mammalian acetyl-CoA carboxylase 1 and 2 Jeffrey W. Corbett, Kevin D. Freeman‐Cook, Richard L. Elliott, Bioorganic & Medicinal Chemistry Letters Medicinal ChemistryBiochemistryNatural SciencesMedicineDrug Development	2009	58

Page 1